Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
256 questions in 49 reviews · Haematology
current versionsNo studies 256 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Casirivimab/imdevimab vs placebo Outcomes · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane | no estimate extracted | NR | No studies |
Casirivimab/imdevimab vs placebo Quality of life at longest · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane | no estimate extracted | NR | No studies |
Casirivimab/imdevimab vs placebo Adverse events: grade 1 to 2 · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane | no estimate extracted | NR | No studies |
Tixagevimab/cilgavimab vs placebo Quality of life at longest · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane | no estimate extracted | NR | No studies |
Tixagevimab/cilgavimab vs placebo Adverse events: grade 1 to 2 · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane | no estimate extracted | NR | No studies |
Tixagevimab/cilgavimab vs placebo Adverse events: grade 3 to 4 within 6 months · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Methylprednisolone vs dexamethasone All‐cause mortality up to 120 days ‐ not reported · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19 Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Methylprednisolone vs dexamethasone Clinical improvement: discharged alive ‐ not reported · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19 Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Methylprednisolone vs dexamethasone Clinical worsening: new need for invasive mechanical ventilation or death ‐ not reported · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19 Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Methylprednisolone vs dexamethasone Serious adverse events ‐ not reported · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19 Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Methylprednisolone vs dexamethasone Adverse events ‐ not reported · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19 Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Methylprednisolone vs dexamethasone Hospital‐acquired infections ‐ not reported · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19 Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Methylprednisolone vs dexamethasone Invasive fungal infections ‐ not reported · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19 Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) vs low‐dose dexamethasone (6 mg to 8 mg) Clinical worsening: new need for invasive mechanical ventilation or death ‐ not reported · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19 Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Improvement of clinical status: time to symptom resolution · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§ Ivermectin for preventing and treating COVID‐19 (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR QoL at longest · people with moderate to severe disease (WHO scale 4–9); all trials contributing results to the summary of findings… Ivermectin for preventing and treating COVID‐19 (2022) · Cochrane | no estimate extracted | NR | No studies |
JAK inhibitors plus standard of care vs standard of care (plus/minus placebo) Outcomes(Time frame of absolute effects) · hospitalised people with confirmed SARS‐CoV‐2 infection Janus kinase inhibitors for the treatment of COVID‐19 (2022) · Cochrane | no estimate extracted | NR | No studies |
Fluvoxamine plus standard care vs placebo plus standard care Symptom resolution · symptomatic people with COVID‐19 Fluvoxamine for the treatment of COVID‐19 (2022) · Cochrane | no estimate extracted | NR | No studies |
Fluvoxamine plus standard care vs placebo plus standard care Quality of life (at longest · symptomatic people with COVID‐19 Fluvoxamine for the treatment of COVID‐19 (2022) · Cochrane | no estimate extracted | NR | No studies |
Fluvoxamine plus standard care vs placebo plus standard care Suicide or suicide attempt (at longest · symptomatic people with COVID‐19 Fluvoxamine for the treatment of COVID‐19 (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Frequency of adverse events at two, six and 12 months · adults with newly diagnosed warm AIHA Disease‐modifying treatments for primary autoimmune haemolytic anaemia (2021) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Overall survival at six and 12 months · adults with newly diagnosed warm AIHA Disease‐modifying treatments for primary autoimmune haemolytic anaemia (2021) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Relapse‐free survival at six and 12 months · adults with newly diagnosed warm AIHA Disease‐modifying treatments for primary autoimmune haemolytic anaemia (2021) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR QOL as measured by validated instruments at 12 months · adults with newly diagnosed warm AIHA Disease‐modifying treatments for primary autoimmune haemolytic anaemia (2021) · Cochrane | no estimate extracted | NR | No studies |
Bamlanivimab/etesevimab vs placebo Mortality by day 60 ‐ not reported · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | NR | No studies |
Bamlanivimab/etesevimab vs placebo Clinical progression · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | NR | No studies |
Bamlanivimab/etesevimab vs placebo Quality of life by day 30 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | NR | No studies |
Casirivimab/imdevimab vs placebo Mortality by day 30 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | NR | No studies |
Casirivimab/imdevimab vs placebo Mortality by day 60 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | NR | No studies |
Casirivimab/imdevimab vs placebo Clinical progression: requirement of IMV (WHO 7, 8 or 9), 1.2g · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | NR | No studies |
Casirivimab/imdevimab vs placebo Quality of life · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | NR | No studies |
Bamlanivimab vs placebo Mortality by day 60 · non‐hospitalised individuals with COVID‐19 SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | NR | No studies |
Casirivimab/imdevimab vs placebo Admission to hospital or death · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | NR | No studies |
Casirivimab/imdevimab vs placebo Adverse events: grade 3‐4 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | NR | No studies |
Casirivimab/imdevimab vs placebo Adverse events: all grades · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | NR | No studies |
Casirivimab/imdevimab vs placebo Serious adverse events · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | NR | No studies |
Sotrovimab vs placebo Mortality by day 60 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | NR | No studies |
Sotrovimab vs placebo Quality of life by day 30 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | NR | No studies |
Bamlanivimab vs placebo Clinical progression/improvement of symptoms · non‐hospitalised individuals with COVID‐19 SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | NR | No studies |
Regdanvimab vs placebo Mortality by day 60Â · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | NR | No studies |
Regdanvimab vs placebo Quality of life by day 30 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | NR | No studies |
Bamlanivimab vs placebo Quality of life · non‐hospitalised individuals with COVID‐19 SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | NR | No studies |
Bamlanivimab vs placebo Quality of life · hospitalised individuals with COVID‐19 (moderate to severe disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | NR | No studies |
Casirivimab/imdevimab vs usual care alone Mortality by day 60 · hospitalised individuals with COVID‐19 (moderate to severe disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | NR | No studies |
Casirivimab/imdevimab vs usual care alone Quality of life · hospitalised individuals with COVID‐19 (moderate to severe disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | NR | No studies |
Casirivimab/imdevimab vs usual care alone Adverse events: grades 3 and 4 by day 30 · hospitalised individuals with COVID‐19 (moderate to severe disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | NR | No studies |
Casirivimab/imdevimab vs usual care alone Serious adverse events by day 30 · hospitalised individuals with COVID‐19 (moderate to severe disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | NR | No studies |
Aspirin (ASA) vs vitamin K antagonist (VKA) Minor bleeding ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | no estimate extracted | NR | No studies |
Aspirin (ASA) vs low molecular weight heparin (LMWH) Major bleeding ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | no estimate extracted | NR | No studies |
Aspirin (ASA) vs low molecular weight heparin (LMWH) Minor bleeding ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | no estimate extracted | NR | No studies |